- United States
- Our innovation
Our innovation
We innovate with purpose to lead where medicine is going.
Our focus areas
Our discovery, product development and supply process
With our cross-functional approach to innovation, deep expertise, and global footprint, we aim to develop therapies for patients by inventing, licensing and acquiring new molecular entities and exploring new pathways and multi-modality treatment approaches.
23-255-richard-tillyer-part-1-who-we-are-1.mp4
23-255-richard-tillyer-part-1-who-we-are-1.mp4
Research & development
We believe there are no limits to what science can do. We work to bring breakthroughs beyond medicine to help transform patients’ lives.
Our pipeline
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
Data science and digital health
Data science and digital health accelerate our R&D engine across the entire value-chain – from target discovery and patient segmentation to drug design, CMC process optimization and all facets of clinical development.
Latest news
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn’s disease and ulcerative colitis
TREMFYA® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn’s disease TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn’s disease, inclusive of those who are biologic-naïve and biologic-refractory Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA®
Contact us
Our R&D leadership team is made up of passionate individuals who are helping to transform the future of healthcare.